$4.18
1.18% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Aquestive Therapeutics, Inc. Stock price

$4.18
+0.78 22.94% 1M
-0.85 16.90% 6M
+2.16 106.93% YTD
+2.60 164.56% 1Y
-0.35 7.73% 3Y
+0.63 17.75% 5Y
-11.87 73.96% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.05 1.18%
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Key metrics

Market capitalization $380.63m
Enterprise Value $407.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.98
P/S ratio (TTM) P/S ratio 6.52
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 25.45%
Revenue (TTM) Revenue $58.36m
EBIT (operating result TTM) EBIT $-15.19m
Free Cash Flow (TTM) Free Cash Flow $-24.91m
Cash position $89.87m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 6.55
EV/Sales forward 7.02
Short interest 14.19%
Show more

Is Aquestive Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Aquestive Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

Buy
100%

Financial data from Aquestive Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
58 58
25% 25%
100%
- Direct Costs 18 18
14% 14%
32%
40 40
59% 59%
68%
- Selling and Administrative Expenses 38 38
1% 1%
65%
- Research and Development Expense 16 16
12% 12%
28%
-14 -14
48% 48%
-24%
- Depreciation and Amortization 1.14 1.14
29% 29%
2%
EBIT (Operating Income) EBIT -15 -15
46% 46%
-26%
Net Profit -26 -26
14% 14%
-44%

In millions USD.

Don't miss a Thing! We will send you all news about Aquestive Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aquestive Therapeutics, Inc. Stock News

Positive
Seeking Alpha
16 days ago
Aquestive Therapeutics Q2 earnings report showed significant beats in EPS and revenue, with a 52% year-over-year revenue increase. The company reported improved operational efficiency and profitability, with a positive non-GAAP adjusted EBITDA of $1.8M and $89.9M in cash, extending their cash runway into 2026. Aquestive provided updates on Anaphylm's progress towards an NDA submission in early ...
Neutral
GlobeNewsWire
16 days ago
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows:
Positive
Seeking Alpha
19 days ago
Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST's robust R&D pipeline, with analysts giving outperform rating and price target increase to $15. AQST recorded significant revenue growth in Q2 2024, with a cash balance of $89.87 million and sufficient funds until the end of ...
More Aquestive Therapeutics, Inc. News

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Head office United States
CEO Daniel Barber
Employees 135
Founded 2004
Website www.aquestive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today